https://www.selleckchem.com/pr....oducts/tolebrutinib-
001). CONCLUSION The concept of TO is a promising tool for measuring patient-level hospital performance and may be useful for identifying important variations in care for patients with RPS. BACKGROUND The mechanism of action of bevacizumab and erlotinib is quite different in the treatment of advanced non-small cell lung cancer (NSCLC). This study sought to compare the two targeted therapies in terms of sequential tumor response metrics. PATIENTS AND METHODS Parameters of radiological tumor response evaluation were assesse
Like
Comment
Share
